Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) Questionnaire Survey of Medical Thyroid Specialists in Korea on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients.

Endocrinology and metabolism (Seoul, Korea)·2026
Same author

Use of Thyroid Hormones in Patients with Hypothyroidism and Euthyroidism in the United States: American Association of Clinical Endocrinology International Collaboration with the THESIS Investigators.

AACE endocrinology and diabetes·2026
Same author

Use of thyroid hormones in euthyroid patients with unexplained fatigue: analyses of aggregate data from European national surveys of professional endocrine society members.

Frontiers in endocrinology·2025
Same author

From awareness to action: evolving endocrinologist practices in obesity treatment in Italy.

Frontiers in endocrinology·2025
Same author

Differences in thyroid hormone prescribing practices between Japan Thyroid Association-certified thyroid specialists and non-certified members: a nationwide survey in Japan.

Endocrine journal·2025
Same author

The use of thyroid hormones in the treatment of euthyroid patients with treatment-resistant depression. Data from a survey of 5695 European national endocrine professional organization members.

Frontiers in endocrinology·2025

Related Experiment Video

Updated: Jan 29, 2026

Robotic Central Pancreatectomy with Roux-en-Y Pancreaticojejunostomy
10:34

Robotic Central Pancreatectomy with Roux-en-Y Pancreaticojejunostomy

Published on: November 20, 2021

6.1K

Octreotide for acromegaly.

Renato Cozzi1, Roberto Attanasio2

  • 1a Ospedale Niguarda Milano, Division of Endocrinology, via Canonica 81, 20154 Milano, Italy. renatocozzi@tiscali.it.

Expert Review of Endocrinology & Metabolism
|February 14, 2019
PubMed
Summary
This summary is machine-generated.

Octreotide effectively treats acromegaly by suppressing growth hormone and shrinking tumors in many patients. While generally safe, potential side effects include worsening glucose metabolism and gallstones.

Keywords:
acromegalygrowth hormoneinsulin-like growth factor-Ioctreotidesomatostatin analoguetumor size

More Related Videos

Protocol for Microplastics Sampling on the Sea Surface and Sample Analysis
10:16

Protocol for Microplastics Sampling on the Sea Surface and Sample Analysis

Published on: December 16, 2016

50.9K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

935

Related Experiment Videos

Last Updated: Jan 29, 2026

Robotic Central Pancreatectomy with Roux-en-Y Pancreaticojejunostomy
10:34

Robotic Central Pancreatectomy with Roux-en-Y Pancreaticojejunostomy

Published on: November 20, 2021

6.1K
Protocol for Microplastics Sampling on the Sea Surface and Sample Analysis
10:16

Protocol for Microplastics Sampling on the Sea Surface and Sample Analysis

Published on: December 16, 2016

50.9K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

935

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Acromegaly is a complex endocrine disorder characterized by excessive growth hormone production.
  • Octreotide has emerged as a cornerstone therapy for managing acromegaly.

Purpose of the Study:

  • To review the efficacy and safety of octreotide in acromegaly treatment.
  • To discuss the role of octreotide in relation to surgical interventions.
  • To explore predictors of treatment response to octreotide.

Main Methods:

  • Literature review of studies on octreotide for acromegaly.
  • Analysis of data on hormonal control, tumor response, and safety profiles.
  • Discussion of treatment strategies comparing pharmacological and surgical options.

Main Results:

  • Octreotide normalizes growth hormone and IGF-I levels in 50-60% of patients.
  • Tumor shrinkage or growth arrest is observed in over half of patients treated with octreotide.
  • Octreotide demonstrates an excellent safety profile, with notable side effects including glucose metabolism alterations and cholelithiasis.

Conclusions:

  • Octreotide is a highly effective and well-tolerated treatment for acromegaly.
  • It plays a crucial role in both primary and adjunctive therapy, offering significant benefits in hormonal control and tumor management.
  • Understanding treatment predictivity is essential for optimizing patient outcomes.